28 Apr 2008 - Micromet, Inc. announced the start of a phase 1 clinical trial with its BiTE® antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers.
MT110 targets the epithelial cell adhesion molecule (EpCAM or CD326), which is highly expressed on colon, lung, breast, prostate, ovarian, gastric and pancreas cancers. Additionally, EpCAM has been found on cancer stem cells of colon, breast, prostate and pancreas cancers. Cancer stem cells are believed to cause metastases and recurrence of these cancers. MT110 is the second BiTE antibody in clinical trials, and the fourth clinical program in Micromet's product pipeline. The first BiTE antibody, MT103 (MEDI-538), is now in phase 1 and phase 2 clinical trials for the treatment of haematological cancers.
"BiTE antibodies enable the patients' own T cells to very efficiently eliminate tumor cells," comments Patrick Baeuerle, Chief Scientific Officer of Micromet, "In various experimental tumor models, we have demonstrated the high therapeutic potential of EpCAM-specific BiTE antibodies, and we are now looking forward to determining the safety and the therapeutic potential of MT110 in patients."
 |
www.bionity.com/news/e/81312 |
|
 |
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/81312 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |